Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05064397
Other study ID # 19385A
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 17, 2021
Est. completion date June 29, 2023

Study information

Verified date July 2023
Source H. Lundbeck A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main goal of this trial is to inform about long-term safety and tolerability of eptinezumab in participants with chronic cluster headache.


Description:

The participants who take part in this trial will be asked to stay in the trial for about a year. The participants will be asked to visit the trial site 7 times during the trial. In between trial site visits, they will have scheduled phone calls with the trial site staff. They will also be asked to keep track of their cluster headaches at home with a headache diary.


Recruitment information / eligibility

Status Completed
Enrollment 131
Est. completion date June 29, 2023
Est. primary completion date June 29, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - The participant has a diagnosis of cCH as defined by International Headache Society (IHS) International Classification of Headache Disorders third edition (ICHD-3) classification with a history of cCH of at least 12 months prior to the Screening Visit. - The participant has a medical history of onset of cluster headache at =50 years of age. - The participant has an adequately documented record of previous abortive, transitional and preventive medication use for cCH, for at least 12 months prior to the Screening Visit. - The participant is able to distinguish cluster headache attacks from other headaches (such as tension-type headaches, migraine). Exclusion Criteria: - The participant has experienced failure on a previous treatment targeting the calcitonin gene-related peptide (CGRP) pathway (anti-CGRP monoclonal antibodies [mAbs] and gepants). - The participant has confounding and clinically significant pain syndromes (for example, fibromyalgia, complex regional pain syndrome). - The participant has a history or diagnosis of chronic tension-type headache, hypnic headache, hemicrania continua, new daily persistent headache, chronic migraine or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), recurrent painful ophthalmoplegic neuropathy, migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or longer than 1 hour). - Participants with a lifetime history of psychosis, bipolar mania, or dementia. Participants with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to Screening Visit. - The participant has attempted suicide or is, at Screening Visit, at significant risk of suicide. - The participant has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism). Other inclusion and exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Eptinezumab
Eptinezumab will be administered per schedule specified in the arm description.

Locations

Country Name City State
Denmark Rigshospitalet Glostrup Glostrup Hovedstaden
Denmark Hospitalsenhed Midt og Regionshospitalet Viborg Viborg Midtjylland
Finland Terveystalo Ruoholahti Helsinki Southern Finland
Finland Terveystalo Turku Pulssi Turku Western Finland
France Hôpital Pierre Wertheimer Bron Rhône
France Hôpital Roger Salengro Lille Nord
France Hôpital de la Timone Marseille Cedex 5 Provence Alpes Cote d'Azur
France Hôpital Cimiez Nice Cedex 1 Côte-d'Or
France Hôpital Lariboisière Paris Île-de-France
France Centre Hospitalier Universitaire de Saint-Étienne Saint-Priest-en-Jarez Rhône
Germany Charité Campus Mitte Berlin
Germany Kopfschmerzzentrum Frankfurt Frankfurt/ Main Hessen
Italy IRCCS Istituto Delle Scienze Neurologiche di Bologna Bologna
Italy Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Fondazione Istituto Neurologico Car... Milano Milan
Italy Fondazione Mondino - Istituto Neurologico Nazionale a Carattere Scientifico IRCCS Pavia
Italy Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - San Raffaele Pisana Rome Roma
Italy Ospedale Molinette - Clinica Neurologica II - Centro Cefalee Turin
Netherlands Brain Research Center - Amsterdam Amsterdam Noord-Holland
Netherlands Canisius-Wilhelmina Ziekenhuis Nijmegen Gelderland
Spain Hospital Universitari Vall d'Hebron Barcelona
Spain Hospital Universitario Marques de Valdecilla Santander Cantabria
Spain Hospital Universitario Virgen del Rocío Sevilla
Spain Hospital Clínico Universitario de Valencia València
Spain Hospital Clínico Universitario de Valladolid Valladolid
United Kingdom The Walton Centre NHS Foundation Trust Liverpool England
United Kingdom King's College Hospital NHS Foundation Trust London England
United States Dent Neurologic Institute - Amherst Amherst New York
United States Michigan Headache and Neurological Institute Ann Arbor Michigan
United States Cleveland Clinic - Neurological Institute Cleveland Ohio
United States Thomas Jefferson University Hospital - Center City Campus Philadelphia Pennsylvania
United States New England Institute for Neurology and Headache Stamford Connecticut

Sponsors (1)

Lead Sponsor Collaborator
H. Lundbeck A/S

Countries where clinical trial is conducted

United States,  Denmark,  Finland,  France,  Germany,  Italy,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Adverse Events From the day of first dose of study drug (Baseline [Week 0]) up to Week 56
Secondary Conversion From Chronic Cluster Headache (cCH) to Episodic Cluster Headache: Number of Participants With No Cluster Headache Attacks for =3 Consecutive Months (=13 Consecutive Weeks) Baseline (Week 0) to Week 48
Secondary Change From Baseline in Weekly Number of Times an Abortive Therapy (Oxygen and/or Triptans) Was Used, Averaged Over the First 4 Weeks After Each Infusion Baseline (Week 0), Weeks 1 to 4, 13 to 16, 25 to 28, and 37 to 40
Secondary Change From Baseline in the Average Number of Weekly Attacks, Averaged Over the First 4 Weeks After Each Infusion Baseline (Week 0), Weeks 1 to 4, 13 to 16, 25 to 28, and 37 to 40
Secondary Change From Baseline in the 5-Point Self-Rating Pain Severity Scale, Averaged Over the First 4 Weeks After Each Infusion Baseline (Week 0), Weeks 1 to 4, 13 to 16, 25 to 28, and 37 to 40
Secondary Response: Number of Participants With =30% Reduction From Baseline in Number of Weekly Attacks Averaged Over the First 4 Weeks After Each Infusion Weeks 1 to 4, 13 to 16, 25 to 28, and 37 to 40
Secondary Response: Number of Participants With =50% Reduction From Baseline in Number of Weekly Attacks Averaged Over the First 4 Weeks After Each Infusion Weeks 1 to 4, 13 to 16, 25 to 28, and 37 to 40
Secondary cCH Remission: Number of Participants With No Cluster Headache Attacks For =1 Month (5 Consecutive Weeks) Baseline (Week 0) to Week 48
Secondary cCH Remission: Number of Participants With No Cluster Headache Attacks For =1 Month (5 Consecutive Weeks Between the First and Second Infusion) Baseline (Week 0) to Week 12
Secondary cCH Remission: Number of Participants With No Cluster Headache Attacks For =1 Month (5 Consecutive Weeks Between the Second and Third Infusion) Week 12 to Week 24
Secondary cCH Remission: Number of Participants With No Cluster Headache Attacks For =1 Month (5 Consecutive Weeks Between the Third and Fourth Infusion) Week 24 to Week 36
Secondary cCH Remission: Number of Participants With No Cluster Headache Attacks For =1 Month (5 Consecutive Weeks Within the First 12 Weeks After the Fourth Infusion) Week 36 to Week 48
Secondary Number of Participants who Received a Transitional Therapy During the Treatment Period Week 0 to Week 48
Secondary Patient Global Impression of Change (PGIC) Score Baseline (Week 0) up to Week 48
Secondary Change From Baseline in Sleep Impact Scale (SIS) Domain Scores Over the Time Baseline (Week 0) up to Week 40
Secondary Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Score at Weeks 4, 16, 28, 40 and 48 Baseline (Week 0) , Weeks 4, 16, 28, 40 and 48
Secondary Health Care Resources Utilization (HCRU) Score Baseline (Week 0) , Weeks 4, 16, 28, 40 and 48
Secondary Change From Baseline in the Work Productivity Activity Impairment: General Health Second Version (WPAI:GH2.0) Sub-Scores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Weeks 4, 16, 28, 40 and 48 Baseline (Week 0) , Weeks 4, 16, 28, 40 and 48
See also
  Status Clinical Trial Phase
Completed NCT02462395 - Anodal Transcranial Direct Stimulation (tDCS) for the Treatment of Chronic Cluster Headache Phase 2/Phase 3
Recruiting NCT01701245 - Prevention and Acute Treatment of Chronic Cluster Headache Compared to Standard of Care Phase 2
Completed NCT01151631 - Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache Phase 3
Recruiting NCT06124534 - Bilateral Occipital Nerve Field Stimulation for the Treatment of dtCCH N/A
Unknown status NCT00399243 - Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache Phase 4
Recruiting NCT05868044 - REsponse to Combined SONS and ONS in Chronic Cluster headachE N/A
Completed NCT01616511 - Pathway CH-1 Long-Term Follow-Up N/A
Completed NCT01359631 - Cephalic Vascular Recording Upon SPG Stimulation N/A
Completed NCT02438826 - A Study of Galcanezumab in Participants With Chronic Cluster Headache Phase 3
Completed NCT02510729 - SPG Neurostimulation in Cluster Patients N/A
Active, not recruiting NCT02168764 - Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache N/A
Completed NCT02797951 - A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache Phase 3
Not yet recruiting NCT05477459 - LSD to Improve Cluster Headache Impact Trial Phase 2
Completed NCT03244735 - Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache: a Prospective Case Series N/A
Terminated NCT02964338 - A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH) Phase 3
Completed NCT01255813 - Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache N/A
Active, not recruiting NCT05023460 - Treatment of Chronic Cluster Headache With TENS and ONS N/A